Effects of continuous or cyclic administration of pamidronate on the skeleton in intact and oophorectomized young rats

Acta Anatomica

Volumn 159, Issue 1, 1997, Pages 42-47

  Ornoy, A ^a  

^a Laboratory of Teratology   (Israel)

Author keywords

Bone resorption; Cyclic therapy; Histomorphometry; Osteoporosis; Pamidronate; Rat

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; FEMALE; METAPHYSIS; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; RAT; SKELETON; SUBCUTANEOUS DRUG ADMINISTRATION; TIBIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM; DIPHOSPHONATES; FEMALE; INJECTIONS, SUBCUTANEOUS; MAGNESIUM; ORGAN SIZE; OVARIECTOMY; PHOSPHORUS; RATS; RATS, WISTAR; TIBIA;

EID: 0031414549     PISSN: 00015180     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Arlot, M.C., P.J. Meunier, P. Chavassieux (1995) Effects of long-term alendronate treatment for postmenopausal osteoporosis on bone histomorphometry (abstract). J Bone Miner Res 10 (suppl 1): 199.
2. Axelrod, D.W., S.L. Teitelbaum (1994) Results of long-term cyclical etidronate therapy: Bone histomorphometry and clinical correlates (abstract). J Bone Miner Res 9(suppl 1): 136.
3. Balena, R., B.C. Toolan, M. Shea, A. Markatos, E.R. Myers, S.C. Lee, E.E. Opas, J.G. Seedor, H. Klein, D. Frankenfield, H. Quartuccio, C. Fioravanti, J. Clair, E. Brown, W.C. Hayers, G.A. Rodan (1993) The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized non-human primates. J Clin Invest 92: 2577-2586.
4. Chesnut, C.H. III, M.R. McClung, K.E. Ensrud, N.H. Bell, H.K. Genant, S.T. Harris, F.R. Singer, J.L. Stock, R.A. Yood, P.D. Delmas, U. Kher, S. Pryor-Tillotson, A.C. Santora II (1995) Alendronate treatment of the post-menopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 99: 144-152.
5. Ferretti, J.L., E. Cointry, R. Capozza, E. Montuori, E. Roldan, A. Perez Lloret (1990) Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1,1 bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats. Bone Miner 11: 101-109.
6. Ferretti, J.L., C.J. Delgado, R.F. Capozza, G. Cointry, E. Montuori, E. Roldan, A. Perez Lloret, J.R. Zanchetta (1993) Protective effects of disodium etidronate and pamidronate against the biomechanical repercussion of betamethasone-induced osteopenia in growing rat femurs. Bone Miner 20: 265-276.
7. Ferretti, J.L., N. Mondelo, R.F. Capozza, G.R. Cointry, J.R. Zanchetta, E. Montuori (1995) Effect of large doses of olpadronate (dimethylpamidronate) on mineral density cross-sectional architecture, and mechanical properties of rat femurs. Bone 16:285S-293S.
8. Fitton, A., D. McTavish (1991) Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41: 289-318.
9. Fleisch, H. (1991) Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcalmic and metastatic bone disease. Drugs 42: 919-944.
10. Fleisch, H. (1993) New bisphosphonates in osteoporosis. Osteoporos Int 2: S15-S22.
11. Fleisch, H., R.G.G. Russell, S. Bisaz, R.C. Muhlbauer, D.A. Williams (1970) The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1: 12-18.
12. Frost, H.M. (1979) Treatment of osteoporosis by manipulation of coherent bone cell populations. Clin Orthop Relat Res 143:228-244.
13. Geddes, A.D., S.M. D'Souza, F.H. Ebetino, K.J. Ibbotson (1994) Bisphosphonates: Structureactivity relationships and therapeutic implications. Bone Miner Res 8:265-306.
14. Guy, J.A., M. Shea, C.P. Peter, R. Morrissey, W.C. Hayes (1993) Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 53:283-288.
15. Harris, S.T., N.B. Watts, R.D. Jackson, H.K. Genant, R.D. Wasnich, P. Ross, P.D. Miller, A.A. Licata, C.H. Chesnut III (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-567.
16. Kippo, K., R. Hannuniemi, T. Virtamo, L. Lauren, H. Ikavalko, V. Kovanen, T. Osterman, R. Sellman (1995) The effects of clodronate on increased bone turnover and bone loss' due to ovariectomy in rats. Bone 17: 533-542.
17. Liberman, U.A., S.R. Weiss, J. Broil, H.W. Minne, H. Quan, N.H. Bell, J. Rodriguezportales, R.W. Downs Jr., J. Dequeker, M. Favus, E. Seeman, R.R. Recker, T. Capizzi, A.C. Santora II, A. Lombardi, R.V. Shan, L.J. Hirson, D. Karpf (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 1437-1443.
18. Marcus, R. (1993) Cyclic etidronate: Has the rose lost its bloom? Am J Med 95: 555-556.
19. Ornoy, A., S. Katzburg (1995) Osteoporosis: Animal models for the human disease; in Ornoy A (ed): Animal Models for Human Related Calcium Metabolic Disorders. Boca Raton, CRC Press, pp 105-126.
20. Plosker, G.L., K.L. Goa (1994) Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 47: 945-982.
21. Seedor, J.G., H.A. Quartuccio, D.D. Thompson (1991) The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 7: 339-346.
22. Shani, M., N.L. Guenther, H. Fleisch, P. Collin. T.J. Martin (1993) Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91: 2004-2011.
23. Shinoda, H., G. Adamek, R. Felix, H. Fleisch, R. Schenk, P. Hagan (1983) Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35: 87-99.
24. Storm, T., G. Tramsborg, T. Steiniche, H.K. Genant, O.H. Sorensen (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322: 1265-1271.
25. 2-vitamin D, on long bones of glucocorticoid-treated rats. Acta Anat 145:61-67.
26. Van Gelder, J.M., E. Breuer, A. Ornoy, A. Schlossman, N. Patlas, G. Colomb (1995) Anticalcification and antiresorption effects of bisacylphosphonates. Bone 16: 511-520.
27. Wronski, T.J., L.M. Dann, K.S. Scott, M. Cintron (1989) Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int 45: 360-366.
28. Wronski, T.J., C.F. Yen (1991) The ovariectomized rat model as an animal model for the postmenopausal bone loss; in Jee WSS (ed): The aged rat model for bone biology studies. Chicago, pp 69-74.
29. Yamazaki, I., H. Yamaguchi (1989) Characteristics of an ovariectomized osteopenic rat model. J Bone Miner Res 4: 13-22.